Ascendis submits FDA application to start cancer trial

A year and a half after announcing its strategy for entering the cancer area, Ascendis Pharma is now preparing to start clinical trials with its first drug candidate.

Photo: Kevin Grønnemann / MedWatch

Just before the new year, the biotech company Ascendis Pharma applied to the US Food and Drug Administration for permission to start running trials with a drug candidate for the treatment of cancer, according a company announcement.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Ambu credits MDR milestone to fastidiousness

All of Medtech firm Ambu’s products already live up to the new EU rules for medical devices, something the firm attributes to a good sense of how much effort living up to the new legislation would require.

China approves Y-mabs drug

Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.

Further reading

Related articles

Latest news

See all jobs